An observational study in Vitiligo, sponsored by CorEvitas. Recruiting at 1 site in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by CorEvitas · Observational
The design is a prospective, observational (non-interventional) registry for adolescent and adult subjects with NSV under the care of a dermatology provider.
The objective of the registry is to create a cohort of adult and adolescent nonsegmental vitiligo (NSV) subjects to evaluate long-term real-world safety and effectiveness of standard of care treatments for NSV. Data collected through the registry may be used to address a range of research questions and use cases, including but not limited to: characterizing the natural history of the disease, evaluating the effectiveness and safety of commercially available medications for the treatment of NSV, providing information to support ongoing risk-benefit evaluation by drug manufacturers and regulators, and research related to drug utilization, disease burden, and unmet needs.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
This study's planned enrollment of 2,500 is above the median of 114 across 67 observational studies indexed under Vitiligo.
Browse Vitiligo studies →CorEvitas is the lead sponsor of 28 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects enrolled in this registry will be treated according to routine clinical care; the assignment of subjects to any treatment will not be determined in advance by the protocol and will be clearly separated from the decision to include subjects in the registry
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals are eligible for enrollment if they meet all of the following criteria:
Adult participants are willing and able to provide required personal information
Cohort 1: Eligible Medication Initiators - Individuals initiating a prescribed eligible NSV medication at the time of enrollment.
Cohort 2: Not Initiating Eligible Medication - Individuals not currently receiving NSV medication at the time of enrollment, Individuals receiving eligible NSV medication prior to enrollment.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in the registry:
- Is participating or planning to participate in a blinded clinical trial for a vitiligo therapy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vitiligo Epidemiology and presentation
The major clinical outcome include an assessment of the epidemiology of Vitiligo. This will be determined using PROs and ClinROs which will be included as part of the case report forms.
Time frame: Every 6 months for 10 years]
Started Aug 2026 (actual). Primary completion is estimated for Dec 2099, 880 months after the start.
Of 25 observational studies under Vitiligo, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10. This study's planned 880 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CorEvitas